ATAI — ATAI Life Sciences NV Income Statement
0.000.00%
Last trade - 00:00
- $320.43m
- $160.40m
- $0.31m
- 19
- 15
- 73
- 28
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 20.4 | 0.233 | 0.314 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 17.2 | 105 | 157 | 144 | 127 |
Operating Profit | -17.2 | -105 | -136 | -143 | -126 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -17.5 | -102 | -137 | -135 | -39.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -17.5 | -102 | -133 | -141 | -40.3 |
Minority Interest | |||||
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -14.1 | -170 | -168 | -152 | -40.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -14.1 | -170 | -168 | -152 | -40.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.032 | -1.03 | -1.1 | -0.982 | -0.249 |
Dividends per Share |